查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
癌症診斷的全球市場 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)
市場調查報告書
商品編碼
1166024

癌症診斷的全球市場 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)

Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 190 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球癌症診斷市場相關調查分析，提供市場趨勢，市場區隔分析，地區分析，企業簡介等資訊。

目錄

第1章 序文

第2章 前提與調查手法

第3章 摘要整理:全球癌症診斷市場

第4章 市場概要

  • 簡介
    • 市場區隔定義
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球癌症診斷市場分析與預測(2017年～2031年)
    • 市場收益預測

第5章 主要考察

  • 癌症診斷的技術開發與新的方法
  • 全球主要國家的癌症的得病率和發生率
  • 產業上COVID-19疫情的影響(價值鏈和短期·中期·長期性影響)

第6章 全球癌症診斷市場分析與預測:各檢驗類型

  • 簡介和定義
  • 主要調查結果/發展
  • 市場金額的預測:各檢驗類型(2017年～2031年)
    • 腫瘤生物標記檢驗
    • 影像檢查
    • 內視鏡檢驗
    • 切片檢查
  • 市場魅力分析:各檢驗類型

第7章 全球癌症診斷市場分析與預測:各用途

  • 簡介和定義
  • 主要調查結果/發展
  • 市場金額的預測:各用途(2017年～2031年)
    • 乳癌
    • 肺癌症
    • 大腸癌症
    • 前列腺癌症
    • 胰臟癌症
    • 血液癌症
    • 卵巢癌症
    • 黑色素瘤
    • 其他的癌症
  • 市場魅力分析:各用途

第8章 全球癌症診斷市場分析與預測:各終端用戶

  • 簡介和定義
  • 主要調查結果/發展
  • 市場金額的預測:各終端用戶(2017年～2031年)
    • 醫院
    • 門診病人手術中心
    • 診斷檢驗室
    • 其他
  • 市場魅力分析:各終端用戶

第9章 全球癌症診斷市場分析與預測:各地區

  • 主要調查結果
  • 市場金額的預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力分析:各地區

第10章 北美的癌症診斷市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場金額的預測:各檢驗類型(2017年～2031年)
  • 市場金額的預測:各用途(2017年～2031年)
  • 市場金額的預測:各終端用戶(2017年～2031年)
  • 市場金額的預測:各國(2017年～2031年)
    • 美國
    • 加拿大
  • 市場魅力分析
    • 各檢驗類型
    • 各用途
    • 各終端用戶
    • 各國

第11章 歐洲的癌症診斷市場分析與預測

第12章 亞太地區的癌症診斷市場分析與預測

第13章 南美的癌症診斷市場分析與預測

第14章 中東·非洲的癌症診斷市場分析與預測

第15章 競爭情形

  • 市場企業 - 競爭矩陣:階層·不同企業規模
  • 市場佔有率分析:各企業(2021年)
  • 企業簡介
    • Abbott
    • Agilent Technologies, Inc.
    • Applied DNA Sciences
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Eli Lilly and Company
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • General Electric Company
    • Hologic, Inc.
    • Illumina, Inc.
    • Menarini Silicon Biosystems
    • QIAGEN
    • Siemens Healthcare GmbH
    • Thermo Fisher Scientific, Inc.
Product Code: TMRGL3637

TMR's report on the global cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global cancer diagnostics market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cancer diagnostics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cancer diagnostics market.

The report delves into the competitive landscape of the global cancer diagnostics market. Key players operating in the global cancer diagnostics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global cancer diagnostics market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Diagnostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cancer Diagnostics Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Developments & New Approaches in Cancer Diagnosis
  • 5.2. Cancer Prevalence & Incidence Rate Globally with Key Countries
  • 5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/ Mid-/Long-term Impact)

6. Global Cancer Diagnostics Market Analysis and Forecast, by Test Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Test Type, 2017-2031
    • 6.3.1. Tumor Biomarker Tests
      • 6.3.1.1. Prostate Specific Antigen Tests
      • 6.3.1.2. Circulating Tumor Cells (CTC) Tests
      • 6.3.1.3. Alpha-fetoprotein (AFP) Tests
      • 6.3.1.4. CA 19-9 Tests
      • 6.3.1.5. CA 125 Tests
      • 6.3.1.6. HER2
      • 6.3.1.7. BRCA
      • 6.3.1.8. KRAS
      • 6.3.1.9. Others
    • 6.3.2. Imaging
      • 6.3.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 6.3.2.2. Positron Emission Tomography (PET) Scan
      • 6.3.2.3. Computed Tomography (CT) Scan
      • 6.3.2.4. Mammography
      • 6.3.2.5. Others
    • 6.3.3. Endoscopy
      • 6.3.3.1. Colonoscopy
      • 6.3.3.2. Bronchoscopy
      • 6.3.3.3. Others
    • 6.3.4. Biopsy
      • 6.3.4.1. Bone Marrow Biopsy
      • 6.3.4.2. Needle Biopsy
      • 6.3.4.3. Endoscopic Biopsy
      • 6.3.4.4. Others
  • 6.4. Market Attractiveness Analysis, by Test Type

7. Global Cancer Diagnostics Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Breast Cancer
    • 7.3.2. Lung Cancer
    • 7.3.3. Colorectal Cancer
    • 7.3.4. Prostate Cancer
    • 7.3.5. Pancreatic Cancer
    • 7.3.6. Blood Cancer
    • 7.3.7. Ovarian Cancer
    • 7.3.8. Melanoma
    • 7.3.9. Other Cancers
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Cancer Diagnostics Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by End-user, 2017-2031
    • 8.3.1. Hospitals
    • 8.3.2. Ambulatory Surgical Centers
    • 8.3.3. Diagnostic Laboratories
    • 8.3.4. Others
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Cancer Diagnostics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Cancer Diagnostics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Test Type, 2017-2031
    • 10.2.1. Tumor Biomarker Tests
      • 10.2.1.1. Prostate Specific Antigen Tests
      • 10.2.1.2. Circulating Tumor Cells (CTC) Tests
      • 10.2.1.3. Alpha-fetoprotein (AFP) Tests
      • 10.2.1.4. CA 19-9 Tests
      • 10.2.1.5. CA 125 Tests
      • 10.2.1.6. HER2
      • 10.2.1.7. BRCA
      • 10.2.1.8. KRAS
      • 10.2.1.9. Others
    • 10.2.2. Imaging
      • 10.2.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 10.2.2.2. Positron Emission Tomography (PET) Scan
      • 10.2.2.3. Computed Tomography (CT) Scan
      • 10.2.2.4. Mammography
      • 10.2.2.5. Others
    • 10.2.3. Endoscopy
      • 10.2.3.1. Colonoscopy
      • 10.2.3.2. Bronchoscopy
      • 10.2.3.3. Others
    • 10.2.4. Biopsy
      • 10.2.4.1. Bone Marrow Biopsy
      • 10.2.4.2. Needle Biopsy
      • 10.2.4.3. Endoscopic Biopsy
      • 10.2.4.4. Others
  • 10.3. Market Value Forecast, by Application, 2017-2031
    • 10.3.1. Breast Cancer
    • 10.3.2. Lung Cancer
    • 10.3.3. Colorectal Cancer
    • 10.3.4. Prostate Cancer
    • 10.3.5. Blood Cancer
    • 10.3.6. Pancreatic Cancer
    • 10.3.7. Ovarian Cancer
    • 10.3.8. Melanoma
    • 10.3.9. Other Cancers
  • 10.4. Market Value Forecast, by End-user, 2017-2031
    • 10.4.1. Hospitals
    • 10.4.2. Ambulatory Surgical Centers
    • 10.4.3. Diagnostic Laboratories
    • 10.4.4. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Test Type
    • 10.6.2. By Application
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Cancer Diagnostics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Test Type, 2017-2031
    • 11.2.1. Tumor Biomarker Tests
      • 11.2.1.1. Prostate Specific Antigen Tests
      • 11.2.1.2. Circulating Tumor Cells (CTC) Tests
      • 11.2.1.3. Alpha-fetoprotein (AFP) Tests
      • 11.2.1.4. CA 19-9 Tests
      • 11.2.1.5. CA 125 Tests
      • 11.2.1.6. HER2
      • 11.2.1.7. BRCA
      • 11.2.1.8. KRAS
      • 11.2.1.9. Others
    • 11.2.2. Imaging
      • 11.2.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 11.2.2.2. Positron Emission Tomography (PET) Scan
      • 11.2.2.3. Computed Tomography (CT) Scan
      • 11.2.2.4. Mammography
      • 11.2.2.5. Others
    • 11.2.3. Endoscopy
      • 11.2.3.1. Colonoscopy
      • 11.2.3.2. Bronchoscopy
      • 11.2.3.3. Others
    • 11.2.4. Biopsy
      • 11.2.4.1. Bone Marrow Biopsy
      • 11.2.4.2. Needle Biopsy
      • 11.2.4.3. Endoscopic Biopsy
      • 11.2.4.4. Others
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Breast Cancer
    • 11.3.2. Lung Cancer
    • 11.3.3. Colorectal Cancer
    • 11.3.4. Prostate Cancer
    • 11.3.5. Pancreatic Cancer
    • 11.3.6. Ovarian Cancer
    • 11.3.7. Blood Cancer
    • 11.3.8. Melanoma
    • 11.3.9. Other Cancers
  • 11.4. Market Value Forecast, by End-user, 2017-2031
    • 11.4.1. Hospitals
    • 11.4.2. Ambulatory Surgical Centers
    • 11.4.3. Diagnostic Laboratories
    • 11.4.4. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Test Type
    • 11.6.2. By Application
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Cancer Diagnostics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Test Type, 2017-2031
    • 12.2.1. Tumor Biomarker Tests
      • 12.2.1.1. Prostate Specific Antigen Tests
      • 12.2.1.2. Circulating Tumor Cells (CTC) Tests
      • 12.2.1.3. Alpha-fetoprotein (AFP) Tests
      • 12.2.1.4. CA 19-9 Tests
      • 12.2.1.5. CA 125 Tests
      • 12.2.1.6. HER2
      • 12.2.1.7. BRCA
      • 12.2.1.8. KRAS
      • 12.2.1.9. Others
    • 12.2.2. Imaging
      • 12.2.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 12.2.2.2. Positron Emission Tomography (PET) Scan
      • 12.2.2.3. Computed Tomography (CT) Scan
      • 12.2.2.4. Mammography
      • 12.2.2.5. Others
    • 12.2.3. Endoscopy
      • 12.2.3.1. Colonoscopy
      • 12.2.3.2. Bronchoscopy
      • 12.2.3.3. Others
    • 12.2.4. Biopsy
      • 12.2.4.1. Bone Marrow Biopsy
      • 12.2.4.2. Needle Biopsy
      • 12.2.4.3. Endoscopic Biopsy
      • 12.2.4.4. Others
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Breast Cancer
    • 12.3.2. Lung Cancer
    • 12.3.3. Colorectal Cancer
    • 12.3.4. Prostate Cancer
    • 12.3.5. Pancreatic Cancer
    • 12.3.6. Ovarian Cancer
    • 12.3.7. Blood Cancer
    • 12.3.8. Melanoma
    • 12.3.9. Other Cancers
  • 12.4. Market Value Forecast, by End-user, 2017-2031
    • 12.4.1. Hospitals
    • 12.4.2. Ambulatory Surgical Centers
    • 12.4.3. Diagnostic Laboratories
    • 12.4.4. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Test Type
    • 12.6.2. By Application
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Cancer Diagnostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Test Type, 2017-2031
    • 13.2.1. Tumor Biomarker Tests
      • 13.2.1.1. Prostate Specific Antigen Tests
      • 13.2.1.2. Circulating Tumor Cells (CTC) Tests
      • 13.2.1.3. Alpha-fetoprotein (AFP) Tests
      • 13.2.1.4. CA 19-9 Tests
      • 13.2.1.5. CA 125 Tests
      • 13.2.1.6. HER2
      • 13.2.1.7. BRCA
      • 13.2.1.8. KRAS
      • 13.2.1.9. Others
    • 13.2.2. Imaging
      • 13.2.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 13.2.2.2. Positron Emission Tomography (PET) Scan
      • 13.2.2.3. Computed Tomography (CT) Scan
      • 13.2.2.4. Mammography
      • 13.2.2.5. Others
    • 13.2.3. Endoscopy
      • 13.2.3.1. Colonoscopy
      • 13.2.3.2. Bronchoscopy
      • 13.2.3.3. Others
    • 13.2.4. Biopsy
      • 13.2.4.1. Bone Marrow Biopsy
      • 13.2.4.2. Needle Biopsy
      • 13.2.4.3. Endoscopic Biopsy
      • 13.2.4.4. Others
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Breast Cancer
    • 13.3.2. Lung Cancer
    • 13.3.3. Colorectal Cancer
    • 13.3.4. Prostate Cancer
    • 13.3.5. Melanoma
    • 13.3.6. Pancreatic Cancer
    • 13.3.7. Blood Cancer
    • 13.3.8. Ovarian Cancer
    • 13.3.9. Other Cancers
  • 13.4. Market Value Forecast, by End-user, 2017-2031
    • 13.4.1. Hospitals
    • 13.4.2. Ambulatory Surgical Centers
    • 13.4.3. Diagnostic Laboratories
    • 13.4.4. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Test Type
    • 13.6.2. By Application
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Cancer Diagnostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Test Type, 2017-2031
    • 14.2.1. Tumor Biomarker Tests
      • 14.2.1.1. Prostate Specific Antigen Tests
      • 14.2.1.2. Circulating Tumor Cells (CTC) Tests
      • 14.2.1.3. Alpha-fetoprotein (AFP) Tests
      • 14.2.1.4. CA 19-9 Tests
      • 14.2.1.5. CA 125 Tests
      • 14.2.1.6. HER2
      • 14.2.1.7. BRCA
      • 14.2.1.8. KRAS
      • 14.2.1.9. Others
    • 14.2.2. Imaging
      • 14.2.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 14.2.2.2. Positron Emission Tomography (PET) Scan
      • 14.2.2.3. Computed Tomography (CT) Scan
      • 14.2.2.4. Mammography
      • 14.2.2.5. Others
    • 14.2.3. Endoscopy
      • 14.2.3.1. Colonoscopy
      • 14.2.3.2. Bronchoscopy
      • 14.2.3.3. Others
    • 14.2.4. Biopsy
      • 14.2.4.1. Bone Marrow Biopsy
      • 14.2.4.2. Needle Biopsy
      • 14.2.4.3. Endoscopic Biopsy
      • 14.2.4.4. Others
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Breast Cancer
    • 14.3.2. Lung Cancer
    • 14.3.3. Colorectal Cancer
    • 14.3.4. Prostate Cancer
    • 14.3.5. Pancreatic Cancer
    • 14.3.6. Ovarian Cancer
    • 14.3.7. Blood Cancer
    • 14.3.8. Melanoma
    • 14.3.9. Other Cancers
  • 14.4. Market Value Forecast, by End-user, 2017-2031
    • 14.4.1. Hospitals
    • 14.4.2. Ambulatory Surgical Centers
    • 14.4.3. Diagnostic Laboratories
    • 14.4.4. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Test Type
    • 14.6.2. By Application
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Abbott
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Agilent Technologies, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Applied DNA Sciences
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Becton, Dickinson and Company
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. bioMerieux SA
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Eli Lilly and Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Exact Sciences Corporation
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. F. Hoffmann-La Roche Ltd.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. General Electric Company
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Hologic, Inc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Illumina, Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Menarini Silicon Biosystems
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. QIAGEN
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Product Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. Siemens Healthcare GmbH
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Product Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview
    • 15.3.15. Thermo Fisher Scientific, Inc.
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Product Portfolio
      • 15.3.15.3. SWOT Analysis
      • 15.3.15.4. Financial Overview
      • 15.3.15.5. Strategic Overview

List of Tables

  • Table 01: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 02: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 04: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 07: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 08: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 09: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 11: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 12: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 13: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 15: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 16: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 17: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 19: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 20: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 23: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 24: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Cancer Diagnostics Market Value Share, by Test Type, 2021
  • Figure 03: Global Cancer Diagnostics Market Value Share, by Application, 2021
  • Figure 04: Global Cancer Diagnostics Market Value Share, by End-user 2021
  • Figure 05: Global Cancer Diagnostics Market Value Share Analysis, by Test Type 2021 and 2031
  • Figure 06: Global Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 07: Global Cancer Diagnostics Market Value (US$ Mn), by Tumor Biomarker Tests, 2017-2031
  • Figure 08: Global Cancer Diagnostics Market Value (US$ Mn), by Prostate Specific Antigen Tests, 2017-2031
  • Figure 09: Global Cancer Diagnostics Market Value (US$ Mn), by Circulating Tumor Cells (CTC) Tests, 2017-2031
  • Figure 10: Global Cancer Diagnostics Market Value (US$ Mn), by Alpha-fetoprotein (AFP) Tests, 2017-2031
  • Figure 11: Global Cancer Diagnostics Market Value (US$ Mn), by CA 19-9 Tests, 2017-2031
  • Figure 12: Global Cancer Diagnostics Market Value (US$ Mn), by CA 125 Tests, 2017-2031
  • Figure 13: Global Cancer Diagnostics Market Value (US$ Mn), by HER2, 2017-2031
  • Figure 14: Global Cancer Diagnostics Market Value (US$ Mn), by BRCA, 2017-2031
  • Figure 15: Global Cancer Diagnostics Market Value (US$ Mn), by KRAS, 2017-2031
  • Figure 16: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017-2031
  • Figure 17: Global Cancer Diagnostics Market Value (US$ Mn), by Imaging, 2017-2031
  • Figure 18: Global Cancer Diagnostics Market Value (US$ Mn), by Magnetic Resonance Imaging (MRI) Scan, 2017-2031
  • Figure 19: Global Cancer Diagnostics Market Value (US$ Mn), by Positron Emission Tomography (PET) Scan, 2017-2031
  • Figure 20: Global Cancer Diagnostics Market Value (US$ Mn), by Computed Tomography (CT) Scan, 2017-2031
  • Figure 21: Global Cancer Diagnostics Market Value (US$ Mn), by Mammography, 2017-2031
  • Figure 22: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017-2031
  • Figure 23: Global Cancer Diagnostics Market Value (US$ Mn), by Endoscopy, 2017-2031
  • Figure 24: Global Cancer Diagnostics Market Value (US$ Mn), by Colonoscopy, 2017-2031
  • Figure 25: Global Cancer Diagnostics Market Value (US$ Mn), by Bronchoscopy, 2017-2031
  • Figure 26: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017-2031
  • Figure 27: Global Cancer Diagnostics Market Value (US$ Mn), by Biopsy, 2017-2031
  • Figure 28: Global Cancer Diagnostics Market Value (US$ Mn), by Bone Marrow Biopsy, 2017-2031
  • Figure 29: Global Cancer Diagnostics Market Value (US$ Mn), by Needle Biopsy, 2017-2031
  • Figure 30: Global Cancer Diagnostics Market Value (US$ Mn), by Endoscopic Biopsy, 2017-2031
  • Figure 31: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017-2031
  • Figure 32: Global Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 33: Global Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 34: Global Cancer Diagnostics Market Revenue (US$ Mn), by Breast Cancer, 2017-2031
  • Figure 35: Global Cancer Diagnostics Market Revenue (US$ Mn), by Lung Cancer, 2017-2031
  • Figure 36: Global Cancer Diagnostics Market Revenue (US$ Mn), by Colorectal Cancer, 2017-2031
  • Figure 37: Global Cancer Diagnostics Market Revenue (US$ Mn), by Prostate Cancer, 2017-2031
  • Figure 38: Global Cancer Diagnostics Market Revenue (US$ Mn), by Pancreatic Cancer, 2017-2031
  • Figure 39: Global Cancer Diagnostics Market Revenue (US$ Mn), by Ovarian Cancer, 2017-2031
  • Figure 40: Global Cancer Diagnostics Market Revenue (US$ Mn), by Blood Cancer, 2017-2031
  • Figure 41: Global Cancer Diagnostics Market Revenue (US$ Mn), by Melanoma, 2017-2031
  • Figure 42: Global Cancer Diagnostics Market Revenue (US$ Mn), by Other Cancers, 2017-2031
  • Figure 43: Global Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 44: Global Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 45: Global Cancer Diagnostics Market Revenue (US$ Mn), by Hospitals 2017-2031
  • Figure 46: Global Cancer Diagnostics Market Revenue (US$ Mn), by Ambulatory Surgical Centers, 2017-2031
  • Figure 47: Global Cancer Diagnostics Market Revenue (US$ Mn), by Diagnostic Laboratories, 2017-2031
  • Figure 48: Global Cancer Diagnostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 49: Global Cancer Diagnostics Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 50: Global Cancer Diagnostics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 51: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 52: North America Cancer Diagnostics Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 53: North America Cancer Diagnostics Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 54: North America Cancer Diagnostics Market Value Share Analysis, by Test Type , 2021 and 2031
  • Figure 55: North America Cancer Diagnostics Market Attractiveness Analysis, by Test Type 2022-2031
  • Figure 56: North America Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 57: North America Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 58: North America Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 59: North America Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 60: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 61: Europe Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 62: Europe Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 63: Europe Cancer Diagnostics Market Value Share Analysis, by Test Type 2021 and 2031
  • Figure 64: Europe Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 65: Europe Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 66: Europe Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 67: Europe Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 68: Europe Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 69: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 70: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 71: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 72: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
  • Figure 73: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 74: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 75: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 76: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 77: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 78: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 79: Latin America Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 80: Latin America Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 81: Latin America Cancer Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
  • Figure 82: Latin America Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 83: Latin America Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 84: Latin America Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 85: Latin America Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 86: Latin America Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 87: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 88: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 89: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 90: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by Test Type , 2021 and 2031
  • Figure 91: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 92: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 93: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 94: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 95: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 96: Company Share Analysis, 2021